Could a Low-Dose start make opioid treatment easier?

NCT ID NCT05450718

Recruiting now Disease control Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tests a low-dose method of starting buprenorphine-naloxone for opioid use disorder, compared to standard guidelines. The goal is to see if this approach is safe, effective, and acceptable to patients. The trial enrolls 70 adults with opioid use disorder who are willing to follow the assigned regimen.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine-naloxone (low-dose initiation)
What this could lead to: If successful, this could make starting buprenorphine treatment easier and more comfortable for people with opioid use disorder, potentially increasing treatment uptake.
What could go wrong: This is a small pilot study with only 70 participants, focused on feasibility. It may not prove effectiveness, and low-dose initiation might not work for everyone or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OPIOID-USE DISORDER

Contacts and locations

Locations

Montefiore Medical Center
RECRUITING

The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.